Corneal lymphangiogenesis - Evidence, mechanisms, and implications for corneal transplant immunology

被引:185
作者
Cursiefen, C [1 ]
Chen, L [1 ]
Dana, MR [1 ]
Streilein, JW [1 ]
机构
[1] Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA 02114 USA
关键词
lymphangiogenesis; cornea; corneal transplantation; immune privilege; antilymphangiogenic therapy;
D O I
10.1097/00003226-200304000-00021
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose. The normal cornea is devoid of blood and lymphatic vessels but can become vascularized secondary to a variety of corneal diseases and surgical manipulations. Whereas corneal (hem)angiogenesis, i.e., the outgrowth of new blood vessels from preexisting limbal vessels, is obvious both clinically and histologically, proof of associated corneal lymphangiogenesis has long been hampered by invisibility and lack of specific markers. This has changed with the recent discovery of the lymphatic endothelial markers vascular endothelial growth factor receptor 3, LYVE-1 (a lymphatic endothelium-specific hyaluronan receptor), Prox 1, and Podoplanin. Methods. We herein summarize the current evidence for lymphangiogenesis in the cornea and describe its molecular markers and mediators. Furthermore, the pathophysiologic implications of corneal lymphangiogenesis for corneal transplant immunology are discussed. Results. Whereas corneal angiogenesis in vascularized high-risk beds provides a route of entry for immune effector cells to the graft, lymphangiogenesis enables the exit of antigen-presenting cells and antigenic material from the graft to regional lymph nodes, thus inducing alloimmunization and subsequent graft rejection. Conclusions. Antilymphangiogenic strategies may improve transplant survival both in the high- and low-risk setting of corneal transplantation.
引用
收藏
页码:273 / 281
页数:9
相关论文
共 87 条
  • [1] LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan
    Banerji, S
    Ni, J
    Wang, SX
    Clasper, S
    Su, J
    Tammi, R
    Jones, M
    Jackson, DG
    [J]. JOURNAL OF CELL BIOLOGY, 1999, 144 (04) : 789 - 801
  • [2] Beasley NJP, 2002, CANCER RES, V62, P1315
  • [3] STEROID INHIBITION OF LIMBAL BLOOD AND LYMPHATIC VASCULAR CELL-GROWTH
    BONEHAM, GC
    COLLIN, HB
    [J]. CURRENT EYE RESEARCH, 1995, 14 (01) : 1 - 10
  • [4] Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries -: Podoplanin as a specific marker for lymphatic endothelium
    Breiteneder-Geleff, S
    Soleiman, A
    Kowalski, H
    Horvat, R
    Amann, G
    Kriehuber, E
    Diem, K
    Weninger, W
    Tschachler, E
    Alitalo, K
    Kerjaschki, D
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (02) : 385 - 394
  • [5] BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141
  • [6] Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO
  • [7] 2-H
  • [8] Vascular endothelial growth factor C induces angiogenesis in vivo
    Cao, YH
    Linden, P
    Farnebo, J
    Cao, RH
    Eriksson, A
    Kumar, V
    Qi, JH
    Claesson-Welsh, L
    Alitalo, K
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) : 14389 - 14394
  • [9] Carreira CM, 2001, CANCER RES, V61, P8079
  • [10] CASLEYSMITH JR, 1980, LYMPHOLOGY, V13, P177